Four to eight thousand people, most of them children in sub-Saharan Africa, die every day from malaria. The spread of drug resistance in Plasmodium falciparum, the parasitic protozoan responsible for the vast majority of lethal malaria cases, is a cause for grave concern with respect to disease control, and renders the development of novel chemotherapeutic agents an urgent task (1) .
The identification of potential targets is now greatly facilitated by the availability of genomic databases ((2); see www.PlasmoDB.org) resulting from an international effort which led to the recent publication of the entire P. falciparum genome sequence (3).
The life cycle of malaria parasites consists of a succession of developmental stages, some of which are characterized by intense cell proliferation, while in others the cell cycle is arrested. P. falciparum infection of the human host is initiated by injection of cell cycle-arrested sporozoites into the bloodstream by an infected Anopheles mosquito. The sporozoites rapidly gain the liver and invade hepatocytes, where asexual multiplication (exoerythrocytic schizogony) occurs, leading to the production of several thousand merozoites. These are released into the bloodstream, and invade erythrocytes, which become the site of another round of asexual multiplication, producing 8-24 new merozoites per infected red blood cell. This phase of the infection (erythrocytic schizogony) is responsible for malaria pathogenesis. The molecular mechanisms through which some of the merozoites, upon red blood cell invasion, arrest their cell cycle and differentiate into male or female gametocytes instead of initiating a new round of schizogony, are not understood. Ingestion of gametocytes by a mosquito is required for transmission to the insect vector, in the midgut of which these cells mature into gametes; for the male gametocytes, this requires sudden release from cell cycle arrest and three rounds of cell division to produce eight gametes. Fertilization in the mosquito midgut then yields a zygote, the only diploid stage in the parasite's life cycle. Meiotic reduction occurs in the ookinete, the motile form into which the zygote rapidly develops. This ookinete crosses the peritrophic membrane and the midgut epithelium, and immobilizes at the epithelium basal lamina.
There it undergoes further development into an oocyst, a site of intense asexual multiplication producing several thousand sporozoites, which are cell-cycle arrested and accumulate in the mosquito's salivary glands, ready to be injected into a vertebrate host during a subsequent blood meal (see www.malaria.org for more information on malaria).
Obviously, the parasite must tightly regulate its cell division status in response to its environment in order to complete its life cycle. The organization of the Plasmodium cell cycle in the different developmental stages, and the molecular mechanisms through which its progression is controlled, are far from being understood (reviewed in (4, 5) ). Erythrocytic schizogony has received more attention from researchers than other dividing stages of the parasite's life cycle, because (i) this process is responsible for pathogenesis, and (ii) it is comparatively easier to obtain biological material from infected red blood cells cultured in vitro than from other stages. A clear correspondence between cellular events occurring during Plasmodium schizogony and the G1, S, G2 and M phases of the "classical" cell cycle has not been established (6) . The invading merozoite is presumably in G1, and DNA synthesis is initiated in the trophozoite approximately 18 hours post invasion. Nuclear divisions ensue in the absence of cytodieresis, resulting in the formation of a schizont; nuclei in a given schizont appear to divide asynchronously (7) , which suggests that cell cycle progression is not dictated solely by fluctuations in the cytoplasmic abundance of cell cycle regulators. It is not clear whether a strict succession of S phases and nuclear divisions occurs, or whether segregation of newly replicated genomes into individual nuclei takes place in a different way. Plasmodial cell multiplication displays other atypical features, such as absence of chromosome condensation, maintenance of the nuclear membrane (cryptomitosis) and presence of intranuclear spindles.
The asynchronicity of nuclear division in a given schizont. renders biochemical analysis of cell cycle progression very difficult. A possible approach to gaining insight into molecular processes of cell cycle control in Plasmodium is to study the function, subcellular localization and other properties of putative regulators such as cyclins and cyclin-dependent protein kinases (CDKs). Several enzymes related to CDKs have been characterized to date in P. falciparum (reviewed in (8) ). Two of these enzymes have been shown to be activated by association with cyclins: PfPK5, a putative homologue of CDK1 (9) , can be activated in vitro by a variety of cyclin-related proteins, including mammalian cyclin H and p25, and Pfcyc-1, the only Plasmodium cyclin characterized so far (10) . Hence PfPK5 appears to display promiscuity in its cyclin requirement. Another atypical functional feature of PfPK5, which to our knowledge has not been reported for CDKs from other organisms, is its ability to autophosphorylate in the presence of a cyclin (10) . Pfmrk, a protein kinase with maximal homology to CDK-activating kinases (CAKs) of the CDK7 family (11) , can also be activated by Pfcyc-1 (12) .
The genome of P. falciparum encodes at least four additional protein kinases related to CDKs (8), suggesting additional cyclins are present as well (in eukaryotes whose genome sequence is known, the number of cyclins is larger than that of CDK catalytic subunits). PCR-based approaches have failed in the identification of malarial cyclins (but not of CDK-related kinases), presumably because of the low level of conservation of Plasmodium cyclins with their counterparts in other eukaryotes. Indeed, Pfcyc-1 identification had to await the in silico search possibilities offered by the availability of genomic databases (10) .
In this report, we describe three novel P. falciparum open reading frames (ORFs) identified in the PlasmoDB database on the basis of their relatedness to cyclins at the primary structure level. We demonstrate that these ORFs encode proteins whose abundance fluctuate during schizogony and which associate with protein kinase activity in parasite extracts, and that one of them is able to activate PfPK5 in vitro. Furthermore, we demonstrate that PfPK5 can be efficiently activated by RINGO, a Xenopus protein unrelated to cyclins but able to activate a subset of mammalian CDKs (13, 14) , pointing to the possibility that cryptic cyclin-like protein may be present in malaria parasites.
EXPERIMENTAL PROCEDURES
Molecular cloning and bacterial expression ---Pfcyc-2. Oligonucleotides were designed for amplification of a 1173 bp region (positions 2956-4129, carrying the cyclin-related sequence) from the 6846-bp ORF (gene PFL1330c in PlasmoDB). The primers contained BamH1 (forward primer :
GGGGTCGACAATAGTTGTATCATTTGTGTGGTC) restriction sites (single underline). After amplification from a P. falciparum cDNA library (kindly provided by A.Craig). with a Taq DNA polymerase (Takara), the PCR product was digested with BamH1 and Sal1 prior to insertion in the pGEX 4T3 vector (Amersham Biosciences). The pGEX-4T3-Pfcyc-2 plasmid was electroporated into E. coli BL21, and (for all three ORF discussed here) the insert was verified by sequencing prior to expression of the recombinant protein.
Protein expression and purification were performed essentially as previously described for GST-Pfcyc-1 (10). Briefly, expression was induced for 4h at 30°C with 0.3 mM isopropyl-β-Dgalactoside (IPTG), after the 250ml culture has reached an OD 600 value of 0.6 in 2xYT medium with 100µg/ml ampicillin. All purification steps were performed at 4°C. Bacterial pellets were lysed with lysosyme and by sonication in 5 ml of lysis buffer (Phosphate buffer saline (PBS) pH 7.5, 0.1% Triton, 1 mM EDTA, 1 mM phenylmethyl-sulfonyl fluoride (PMSF) and Complex TM mixture protease inhibitor tablet from Roche Molecular Biochemicals). Lysates were cleared by centrifugation (11000 rpm, 4°C, 30 min.) and the soluble fraction was incubated for 1h30 at 4°C under mild agitation with 0.5 ml of glutathione-agarose resin (Amersham). The slurry was washed in lysis buffer and the GST-Pfcyc-2 fusion protein was eluted with elution buffer (30mM Tris pH 8.0, 15 mM NaCl, 2 mM glutathione).
Pfcyc-3:
The entire ORF (PFE0920c in PlasmoDB) was cloned into the BamH1 and Sal1 restriction sites of the pMALc2x vector (New England Biolabs) after amplification from P. Expression and purification of MBP-RINGO (ls26 clone) were performed as described elsewhere (13) . Peptides were designed with a terminal cysteine residue (except for Pcyc-3, whose chosen peptide contains an internal cysteine) and coupled to rabbit albumin using 3-maleimidobenzoic acid Nhydroxysuccinimide ester (17 The kinase assays were performed in a standard reaction as described below. 
Kinase assays---

RESULTS
In silico identification of three P. falciparum ORFs related to cyclins ---We performed BLASTP searches of the PlasmoDB database, using as queries a variety of cyclin sequences from diverse organisms, and also used the "Text search" tool on the PlasmoDB website, using the word "cyclin" as a query. This enabled us to identify the previously characterized Pfcyc-1 gene (10), as well as three additional ORFs, all of which displayed maximal homology to various cyclins upon BLASTP analysis of generalist databases (Table 1) .
Pfcyc-2.
The first novel ORF we identified in this search is located on chromosome 12 (gene PFL1330c in PlasmoDB) comprises two exons and potentially encodes a large protein: the Pf annotation predicts a 2281-residue polypeptide, which includes a 390 aminoacid sequence (residues 986-1376) that meets the criteria for recognition as a cyclin in the Pfam conserved domain database (Table 1) . Indeed, performing a BLASTP analysis using this region as a query to screen generalist databases, we found that all high score entries were cyclins from a variety of organisms, most of them mitotic (A and B-type) cyclins. Despite this consistency, the homology is rather low (13% identity over the 390-residue cyclin-like region with a cyclin from A. pectinifera, increasing to 40% identity over the most conserved 80 residues within the cyclin box). An alignment of this region with two of the most closely related cyclins is shown in Fig. 1A .
To verify that the Pfcyc-2 cyclin-like region was part of a much larger polypeptide, as predicted by the algorithms in PlasmoDB, we performed RT-PCR experiments (data not shown) with P. falciparum mRNA and primers designed from the predicted ends of the entire ORF. This enabled us to amplify the entire region (2.7 kb) lying 3' to the cyclin-related sequence. Sequence analysis demonstrated that the 5' boundary of the intron is shorter from that predicted in PlasmoDB: in our cDNA the intron was located between positions 6170 and 6327 (counting from the initiation codon), instead of positions 6104 and 6327 as predicted in the database. We were unable to obtain PCR product starting at the predicted translation initiation site, presumably because of the large size of the mRNA. However, we obtained a PCR product extending 1.3 kp upstream of the cyclin-related region.
Taken together, these experiments demonstrate that the Pfcyc-2 mRNA is at least 5.2 kb in size (from nt 1633 to 6846 in the PlasmoDB entry). Furthermore, sequence analysis showed that a continuous ORF embeds the cyclin-related region, as predicted on PlasmoDB (although we noticed a one-base deletion in a stretch of As outside the cyclin region (position 4376), probably arising from polymerase slippage during reverse transcription --this is a common occurrence with the AT-rich malarial genes). 
Pfcyc
Pfcyc-4.
The last cyclin-related sequence identified in this search was first found in PlasmoDB as a 74-aminoacid ORF located on chromosome 13. Subsequent experimental data from
Western blot experiments (see below) suggested that the ORF should actually be larger, and we therefore re-examined the latest version of PlasmoDB. Indeed, the Pfcyc-4 ORF had been updated and now gene prediction algorithms all predicted ORFs between 202 and 262 aminoacids, the discrepancies being due to differences in the number and boundaries of introns. RT-PCR using primers designed to discriminate between the three models, followed by sequence analysis of the amplicons, allowed us to establish the validity of the 5-exon Pf annotation prediction (gene PF13_0022). The 262-residue, 31 kDa polypeptide potentially encoded by the Pfcyc-4 ORF is recognized as a cyclin by the SMART conserved domain database (entry: smart00385.5), and contains two cyclin boxes, like the recently described ania-6-type cyclins (22) to which it appears to be related.
Interestingly, the highest BLASTP scores for the entire Pfcyc-4 ORF correspond to uncharacterized ania-like cyclins from insects (33% identity with an Anopheles cyclin), followed by ania cyclins from plants and mammals (see Fig. 1C for an alignment) . Surprisingly, all amplicons obtained from several independent RT-PCR experiments had a frame-shift mutation (deletion of one base in a stretch of 7
As) at position 565, resulting in a predicted polypeptide containing one cyclin box instead of two (see Fig 1C) . As will be shown below, the N-terminal part of the protein is sufficient to display proteinkinase binding properties. . In all cases, negative controls in which reverse transcriptase had been omitted gave no signal, allowing us to exclude that amplification bands derived from contaminating genomic DNA. At the time we performed this series of RT-PCR experiments, Pfcyc-4-specific oligonucleotides were not available. We were however able to demonstrate that an amplification product corresponding to the spliced transcript was readily obtained from a blood stages cDNA library, suggesting that the gene is expressed in these stages (Fig. 2 ). This was confirmed by Western blot analysis (see below).
Expression of the cyclin-related genes in erythrocytic stages. (1°) mRNAs. ---
(2°) Proteins. We next obtained peptide-derived antibodies against the polypeptides encoded by the four cyclin-related genes. The antibodies against peptides derived from Pfcyc-1, Pfcyc-2 and Pfcyc-4 recognized their cognate recombinant protein, and showed no cross-reactivity with non-cognate cyclin-like proteins (Fig. 3A) . Antibodies directed against Pfcyc-3 failed to produce a signal on fused to GST. After identifying a larger Pfcyc-4 ORF in PlasmoDB, we prepared another plasmid (Pfcyc-4/CB) containing the entire predicted coding region (carrying a frameshift deletion at residue 565, and therefore expressing on full cyclin box, see above and Fig. 1C) ). Expression was successful for Pfcyc-1, Pfcyc-2, Pfcyc-4/CB and Pfcyc-4/NT; however, we were unable to express Pfcyc-3 as a GST fusion protein. We therefore switched to the expression system generating a fusion with the maltose-binding protein (MBP). This somewhat improved the yield, but the total amount obtained was not sufficient to perform some of the experiments described below with this particular protein.
We performed pull-down experiments to determine whether the recombinant cyclin-related molecules were able to associate with a kinase activity in parasite extracts. Glutathione-agarose beads were coated with similar amounts of either GST alone (as a negative control), GST-Pfcyc-1, GSTPfcyc-2, GST-Pfcyc-4/NT or GST-Pfcyc-4/CB (recombinant Pfcyc-3 was not available in sufficient amount to be included in this series of experiments). The beads were then incubated in either parasite extract (asynchronous asexual stages) or parasite lysis buffer alone (without parasite material) and washed. The material bound to the beads was subsequently assayed for histone H1 kinase activity (Fig. 4) . No such activity was detectable in all samples that had not been in contact with the parasite protein extract (lanes 6-9), indicating that the H1 kinase activity is not of bacterial origin.. In those samples that had been incubated in parasite extract, a weak signal, presumably originating from nonspecific binding of protein kinases to the beads, was present in the "GST alone" negative control (not shown). A signal of identical intensity was observed on the beads coated with GST-Pfcyc-2 (lane 3), indicating that this particular recombinant protein did not associate specifically with a kinase activity under these conditions (and, incidentally, provides a valuable additional negative control). In contrast, a strong signal was detected when the beads had been coated with Pfcyc-1 (lane 2) and Pfcyc-4 (lanes 4 and 5). In the latter case, the recombinant protein containing only the 74 N-terminal residues of Pfcyc-4 was as efficient as the larger protein to pull down the kinase activity (compare lanes 4 and 5).
These data strongly suggest that the proteins encoded by the Pfcyc-1 and Pfcyc-4 genes are able to bind to a protein kinase present in the parasite extract, and are consistent with the in vitro cyclin activity that we reported previously for Pfcyc-1 (10).
Immunoprecipitation of histone H1 kinase activity using antibodies against four P. falciparum cylin-related proteins. ---The ability of the malarial cyclin-related proteins to associate with a kinase activity from parasite extracts was also investigated by immunoprecipitation of the native proteins in parasite extracts using the monospecific, immunopurified antibodies described above (Fig. 5) . This allowed us to test a possible association of Pfcyc-3 (which was not produced in sufficient amounts in E. coli to allow us to perform the pull-down experiment described above) with a kinase activity in parasite extracts. Immunoprecipitates obtained with Pfcyc-1 and Pfcyc-4 antibodies contained a high level of histone kinase activity (lanes 2 and 5), thereby independently confirming the pull-down data.
Immunoprecipitated Pfcyc-2 and Pfcyc-3 (lanes 3 and 4, respectively) also gave signals that were repeatedly higher than background (lanes 6 and 7), albeit to a lesser extent than Pfcyc-1 and Pfcyc-4.
This suggests that all four cyclin-related protein associate with histone H1 kinase activity present in the parasite extract (see discussion).
Activation of PfPK5 by recombinant Pfcyc-3.---
We demonstrated earlier that PfPK5, the malarial protein kinase that is most closely related to CDK1, displays a relaxed specificity with respect to the cyclins that can activate it in vitro (10) . We therefore tested the ability of the three novel recombinant cyclin-related proteins to activate His-tagged PfPK5. MBP-Pfcyc-3 stimulated PfPK5 activity against an exogenous substrate, the carboxy-terminal domain (CTD) of RNA polymerase II, in a dose-dependent manner, whereas the MBP moiety alone showed no effect (Fig.   6A ). The level of PfPK5 activation by MBP-Pfcyc-3 was heavily dependent on the batches of recombinant proteins, with some preparations lacking activity altogether. MBP-Pfcyc-3 was poorly expressed in E. coli, and the amounts of protein obtained were in general too low to allow quantification of the full-length fusion protein prior to performing the kinase assay (this explains why the amount of MBP-Pfcyc-3 used in these experiments is expressed in the Fig. legend as the volume of purified protein rather than as the mass of recombinant protein). Therefore, it appears that the "specific activity" of MBP-Pfcyc-3 in this assay was relatively high compared to that of GST-Pfcyc-1 (which was routinely used in microgram amounts) . GST-Pfcyc-2 never displayed any significant PfPK5-activating activity is this series of experiments, against either CTD or histone H1 , while some batches of GST-Pfcyc-4 displayed marginal levels of activity (data not shown). GST-Pfcyc-1 used as a positive control repeatedly had the previously described (10) ability to stimulate PfPK5.
An unexpected property of PfPK5 was its ability to autophosphorylate in the presence of GSTPfcyc-1 (10). To determine whether the enzyme would also display this property in the presence of MBP-Pfcyc-3, we performed kinase assays using both recombinant cyclins, in such conditions as to obtain a similar level of PfPK5 activity towards CTD (Fig. 6B, compare lanes 3 and 4) . It is clear that PfPK5 autophosphorylates in the presence of Pfcyc-1 (lanes 4 and 5) but not in the presence of Pfcyc-
(lane and 6).
Activation of PfPK5 by RINGO---The in silico searches which lead to the identification of
Pfcyc-1 to -4 were based solely on homology to cyclins. However, in other systems there are examples of CDKs being activated by proteins which show no obvious sequence homology to cyclins.
For example, mammalian p25, an activator of CDK5 with no relatedness to cyclins at the primary structure level, is very similar to cyclins in its tri-dimensional structure as it shares the so-called "cyclin fold"; we demonstrated earlier that p25 is an efficient activator of PfPK5 (10) . Another "noncyclin" activator of CDK1 and CDK2, RINGO, has more recently been described (13, 14) . As shown in Fig. 7 , RINGO is an efficient activator of PfPK5. Addition of increasing amounts of recombinant RINGO (from 0 to 250 ng) to a fixed amount of PfPK5 (1 µg) resulted in a linear increase in kinase activity (Fig. 7A, lanes 2 to 10) . With larger amounts of RINGO, a plateau effect was observed, as expected (data not shown). Obviously, we verified (i) that the preparations of MBP-RINGO used for these experiments did not carry any intrinsic kinase activity, and (ii) that the MBP moiety alone has no effect on PfPK5 activity (data not shown, but see Fig. 6A , lanes 7-9). As is the case with Pfcyc-1 but not Pfcyc-3 (Fig. 6B ), PfPK5 appears to undergo autophosphorylation in the presence of RINGO (Fig. 7B, lane 4) ; however, since the RINGO protein itself is efficiently phosphorylated by PfPK5 (Fig. 7B, lanes 4 and 5) , we cannot at this stage exclude that the band observed at 34 kDa in Fig. 7B is a RINGO degradation product rather than phosphorylated PfPK5. Although it is difficult to accurately quantify the stimulatory effect of the various activators on PfPK5 because of the very low level of basal activity of the kinase, RINGO clearly appears to be a stronger activator of the malarial CDK than other recombinant proteins (such as Pfcyc-1) tested at similar concentrations: 20-fold more GST-Pfcyc-1 than MBP-RINGO was needed to generate a similar signal from a fixed amount of PfPK5 (Fig. 7C ). This is in agreement with our independent estimations of a PfPK5 activation factor of up to three orders of magnitude by GST-Pfcyc-1 (10) and of more than four orders of magnitude by GST-RINGO (this study; data not shown).
DISCUSSION
Identification of three novel potential cell cycle regulators in malaria parasites. P lasmodium
post-genomics is coming of age, and the availability of sequence databases for several species of malaria parasites has revolutionized the study of the molecular biology of this important genus of pathogenic organisms. An obvious benefit of this recent development is the ease with which putative homologues of gene products of interest (notably with respect to potential drug or vaccine targets) can be identified, cloned and characterized (25) . Here we report the identification and preliminary characterization of three genes encoding novel putative P. falciparum cell cycle regulators.
The purpose of this study was to identify P. falciparum regulators of cyclin-dependent kinases.
In addition to Pfcyc-1 (10), searches of the P. falciparum genomic database has revealed three additional cyclins-related proteins, all of which appear to be expressed in blood stages of the infection.
The three different molecules for which Western blot analysis was possible, Pfcyc-1, -2 and -4, have characteristic patterns of expression, which may indicate that they have distinct and non-redundant roles in the malaria cell cycle. For example, the 30-kDa form of Pfcyc-4 is present in high levels in segmenters and in rings, but in lower levels in trophozoites, in marked contrast with Pfcyc-1, which peaks in trophozoites, similar to PfPK5, a P. falciparum CDK1 putative homologue (8) .
Furthermore, these molecules appear to undergo differential processing and/or degradation processes.
Differential splicing modifications cannot be ruled out as a possible explanation for the presence of some of the observed protein species. Indeed, each of the cyclin genes identified in the present study would warrant a detailed study of the structure of its mRNA(s) and of the post-translational modifications its products undergoes during the life cycle of the parasite. cDNA encoded only one of the two cyclin boxes because of a frameshift deletion (Fig 1C) , the recombinant protein was able to associate to a kinase activity. Furthermore, a short region of Pfcyc-4
Biochemical properties of the novel
(the 75 N-terminal residues) is sufficient to display this kinase-binding activity. This study also
shows that Pfcyc-1, for which available functional data were thus far restricted to the demonstration of PfPK5 activation in vitro, associates with a histone kinase activity in parasite extracts. In contrast, the cyclin-like domain contained within the (much larger) Pfcyc-2 ORF was unable to pull down a kinase activity from parasite extracts, although immunoprecipitates from such extracts obtained by using a mono-specific anti-Pfcyc-2 antibody contained levels of histone H1 kinase activity that were significantly above background. A possible explanation for this apparent discrepancy is that the domain expressed in recombinant Pfcyc-2 may lack regions that are essential for interaction with the kinase subunit. An alternative possibility is that the cognate catalytic subunit (see below), or an additional required factor, was not present in sufficient amount in free, unbound form in the parasite extracts to allow detection under these conditions. While the immunoprecipitation data are consistent with a cyclin function for Pfcyc-2, we cannot formally exclude at this stage that they arose from crossreactivity of the antibody to a different protein present in the parasite extract: although the immunopurified anti-Pfcyc-2 antibody does not show any cross-reactivity with recombinant Pfcyc-1 or Pfcyc-4 ( Fig. 3A) , cross-reactivity with another, as yet unidentified protein with cyclin-like activity, is possible (albeit unlikely). A scan of the entire P. falciparum genome with the sequences of the peptides used for immunization showed that these sequences are indeed unique, and that no closely related sequence are found in PlasmoDB.
Notwithstanding Pfcyc-2, the present study brings to three the number of parasite proteins with demonstrated cyclin properties (Pfcyc-1, -3 and -4). Their identity was uncovered on the basis of overall homology levels, but none of these sequences possess specific motifs found in cyclins in other systems. For example, the MRAIL motif which, in many cyclins, mediates interactions with the RXL motif present in substrates or regulators (26, 27) , is not present in the plasmodial molecules. The "destruction box" targeting proteins (including many cyclins) for ubiquitin-dependent proteolysis (28, 29) is also apparently missing. In this respect, it is worth mentioning that malaria parasites appear to possess a ubiquitin pathway (30); whether or not it is used to regulate cyclin levels remains to be investigated. In particular, it would be of interest to determine whether some of the high molecular mass bands observed on Western blots (Fig. 3 ) may be poly-ubiquinated forms of the proteins.
We identified Pfcyc-3 as yet another cyclin (and the second one from P. falciparum, the first one being Pfcyc-1) able to activate PfPK5 in vitro, confirming the promiscuity of this kinase with respect to its activating partners. Obviously, the relevance of this finding remains to be established in an in vivo context. Interestingly, Pfcyc-1 and Pfcyc-3 have differential effects on PfPK5: in conditions where both cyclins activate the kinase to a similar level towards an exogenous substrate (Fig. 6B) , it is only in the presence of Pfcyc-1 that autophosphorylation occurs (the non-plasmodial activator RINGO behaves like Pfcyc-1 in this respect (Fig. 7B) ). Autophosphorylation has to our knowledge not been documented in CDKs from other systems, even in vitro. The identity of the target residue, and whether or not this phenomenon has any physiological relevance, remain to be determined. It is still not clear whether or not P. falciparum possesses a CDK-activating kinase (CAK); Pfmrk, a kinase with maximal homology to the mammalian CAK CDK7, can be activated in vitro by Pfcyc-1 and by mammalian cyclin H to phosphorylate histone H1, but does not appear to use PfPK5 as a substrate in these conditions (10) . The observation that RINGO, which activates mammalian CDKs in a CAK-independent manner (14) , is a powerful activator of PfPK5, may suggest that this enzyme may be regulated in a similar (CAK-independent) way in vivo.
Cryptic cell cycle regulators in the P. falciparum genome? In eukaryotic systems where cell cycle control is better understood, the number of cyclins is generally larger than that of catalytic subunits, and in several instances a given catalytic subunit can be activated by a number of different cyclins, each of which confers different catalytic properties (e.g. in terms of substrate specificity) to the kinase subunit (31, 32) . A superficial examination of the P. falciparum genome CDK and cyclin content, based on sequence homology, seems to suggest that the number of cyclins is surprisingly small. However, the observation that RINGO (this study) and p25 (10), two proteins with no homology to cyclins at the primary structure level, are efficient activators of a malarial CDK, together with the fact that approximately 50% of the ORFs in the Plasmodium genome are not related to any known protein (3), leaves open the possibility that "cryptic" cyclin functional homologues may be present in Plasmodium. It relevant to mention here that no obvious homologues of RINGO or p25
have yet been identified in PlasmoDB.
Reconstructing the Plasmodium cell cycle control network. A possible avenue to overcome the problem of identification of cryptic CDK regulators is to exploit genomic databases in a mass spectrometry-based approach, in which proteins interacting with a given tagged CDK (or cyclin) can be purified from parasite extracts by affinity chromatography and hydrolized into peptides. These can then be subjected to mass spectrometry analysis, and identified against genomic databases (33, 34) .
This should allow us not only to identify novel (possibly cryptic) functional homologues of cell cycle regulators, but also to determine which already characterized molecules form cognate CDK-cyclin pairs. This presents a particular interest in the context of investigations into regulatory networks of such a phylogentically isolated group of organisms as the Apicomplexa, where the precise function of proteins can often not be predicted from sequence alone. For example, one would not have predicted that PfPK5, a putative CDK1 homologue, would be activated by Pfcyc-1, a protein that is most closely related, at the primary structure level, to the cyclin H family, and would therefore be expected to specifically activate a CDK7 homologue (for an extended discussion of this topic, see ref. (5)). Two of the cyclins described here clearly display primary structure relatedness to well defined classes of cyclins, as determined by BLAST analysis: the Pfcyc-2 sequence is more related to mitotic (A and B)
cyclins (despite lacking a MRAIL motif, see above and Fig. 1A) , and Pfcyc-4 appears to fall within the ania-6 family of cyclins (22) . Members of the latter family appear to play a role in transcription control in some mammalian cell types, and have been show to associate with CDK-related kinases of the PITSLRE family (22) . Several isoforms of PITSLRE kinases are found in mammalian cells, and play a role in a variety of processes, including cell division (35) and transcriptional control (36) .
Pfcrk-1 is a putative malarial member of this kinase family (37) , and it would be tempting to speculate that Pfcyc-4 may be an activating partner for this enzyme. However, in view of the unexpected observations (discussed above) concerning the cyclins capable of activating PfPK5, and considering the well-known limitations of BLAST analysis-based protein classification (38) , it would be dangerous to predict precise functions (and/or kinase subunit partners) for the cyclins described in this work on the sole basis of their sequence. Clearly, the function of these elements must be explored experimentally. To this end, we envisage to adopt the RNA interference approach, which has recently been applied successfully to essential plasmodial genes (39-41). Lane 6 is the negative control (reaction with histone H1 but no recombinant proteins). After electrophoresis, the gel was autoradiographed for 30 minutes. O Anti-Cyc1
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